Navigation Links
Study shows that high-dose, high-frequency interferon produces no additional benefit

CAMBRIDGE, MA April 15, 2008 -- Results of a phase IV, open label, head-to-head study of intramuscular AVONEX and high-dose, high-frequency subcutaneous Rebif (interferon beta-1a) provide clinical evidence that the two drugs show similar efficacy over 18 to 30 months of continued therapy in patients with relapsing-remitting multiple sclerosis (RRMS). These data are published in the April 2008 issue of the Current Medical Research and Opinion journal.

The Prospective and Retrospective Long-Term Observational Study of AVONEX and Rebif (PROOF), involved 217 patients with 136 completing a median of 25.9 months of AVONEX 30 mcg once weekly (n=69) and a median of 22.2 months Rebif 44 mcg three times weekly (n=67).

Led by a group of principal investigators including Dr. T. Jock Murray of Division of Neurology, Dalhousie MS Research Unit, Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia; Canada; and Dr. Alireza Minagar, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana, the study provides further clinical evidence that the dose and frequency of treatment shows no advantage on delivering better efficacy.

Upon evaluation of baseline disability, Expanded Disability Status Scale (EDSS) scores showed no statistically significant differences between the two treatment groups during the prospective portion of the study, with sustained disability progression similar for both: 25.8 percent for AVONEX vs. 26.7 percent for Rebif. Additional key findings include:

  • Relapse rates, MRI endpoints of brain parenchymal fraction, T1 lesion volume, T2 lesion volume, number of new/enlarging T2 lesions and gadolinium enhancing (Gd+) lesion volume and count were also comparable between both groups.

  • In addition, 19 percent of patients taking Rebif tested positive for neutralizing antibodies (NAbs) at end of treatment compared with zero percent taking AVONEX.

Given that this data shows similar efficacy between AVONEX and Rebif, physicians and patients with relapsing-remitting MS may want to consider factors that influence ease of use and adherence to treatment such as convenient administration, injection tolerability and immunogenicity when selecting therapy, said Dr. Murray.

These results are in accordance with a growing body of evidence from other trials that suggest that interferons show similar efficacy regardless of dose or frequency, said Thorsten Eickenhorst, MD, vice president of Medical Affairs at Biogen Idec. AVONEX is the only once-a-week therapy that has proven to slow disability and offers a low incidence of injection site reactions.

AVONEX is the number one prescribed treatment for relapsing forms of multiple sclerosis (MS) worldwide, and is the only once-a-week MS therapy that is effective after the first attack. AVONEX is also proven to slow the progression of physical disability (as shown by 37 percent reduction over two years) and reduce the number of relapses. Nearly nine out of 10 patients remained fully functional after five years. AVONEX has been proven effective in clinical trials for up to three years.


Contact: Kathleen Vigneault
Manning Selvage & Lee

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back ... to choose from, the possibilities are endless. Users have full control over angle of ... Pulse masking effects, users are sure to get heads to turn. , ProPanel: Pulse ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... affecting the health care in America. As people age, more care is needed, ... costs are rising, and medical professionals are being overworked. The forgotten part of ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print component of “Supporting ... Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation of approximately 250,000 ... through a vast social media strategy and across a network of top news ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices in America", ... delves into an array of issues that are presently affecting Americans. Dedicated to providing ... this show is changing the subjects consumers focus on, one episode at a time. ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Dr. ... Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., ... observed that both STEMI and Sepsis conditions present in similar ways and require time-critical ...
Breaking Medicine News(10 mins):
(Date:11/29/2015)... Germany , Nov. 29, 2015  At ... invites attendees to experience the most complete mobile C-arm ... on display is Ziehm Vision RFD 3D, the world,s ... 16 cm edge length per scan volume. In addition, ... first fully motorized mobile C-arm in four axes which ...
(Date:11/27/2015)... YORK , November 27, 2015 ... system is set to go online. The potential to ... processes is vast and far from fully exploited as ... to patient health records, either via mobile tablet or ... ) --> ) --> ...
(Date:11/26/2015)... , November 27, 2015 /PRNewswire/ ... --> Medical ... response system (PERS) market is ... 5 years with APAC being ... to see a high CAGR ...
Breaking Medicine Technology: